Background: Lower body-mass index (BMI) in late life has been associated with an increased risk of dementia, and weight loss has been associated with more rapid decline in Alzheimer’s disease (AD) dementia.
Objective: To explore the association between BMI and cortical amyloid burden in clinically normal (CN) elderly at risk for AD dementia.
Methods: Cross-sectional analyses were completed using baseline data from the Harvard Aging Brain Study, consisting of 280 community-dwelling CN older adults aged 62–90. Assessments included medical histories and physical exam, Pittsburgh compound B (PiB) positron emission tomography (PET) amyloid imaging, and apolipoprotein E ɛ4 (APOE4) genotyping. For the primary analysis, a general linear regression model was used to evaluate the association of BMI with PiB retention. Covariates included age, sex, years of education, and APOE4 carrier status. Secondary analyses were performed for BMI subdivisions (normal, overweight, obese), APOE4 carriers, and BMI×APOE4 interaction.
Results: In the primary analysis, greater PiB retention was associated with lower BMI (β = –0.14, p = 0.02). In the secondary analyses, APOE4 carrier status (β= –0.27, p = 0.02) and normal BMI (β= –0.25, p = 0.01), as opposed to overweight or obese BMI, were associated with greater PiB retention. The BMI×APOE4 interaction was also significant (β= –0.14, p = 0.04).
Conclusions: This finding offers new insight into the role of BMI at the preclinical stage of AD, wherein lower BMI late in life is associated with greater cortical amyloid burden. Future studies are needed to elucidate the mechanism behind this association, especially in those with lower BMI who are APOE4 carriers.
LainscakM, von HaehlingS, DoehnerW, AnkerSD (2012) The obesity paradox in chronic disease: Facts and numbers. J Cachexia Sarcopenia Muscle3, 1–4.
2.
WhitmerRA, GundersonEP, Barrett-ConnorE, QuesenberryCPJr, YaffeK (2005) Obesity in middle age and future risk of dementia: A 27 year longitudinal population based study. BMJ330, 1360.
AttiAR, PalmerK, VolpatoS, WinbladB, De RonchiD, FratiglioniL (2008) Late-life body mass index and dementia incidence: Nine-year follow-up data from the Kungsholmen Project. J Am Geriatr Soc56, 111–116.
5.
HughesTF, BorensteinAR, SchofieldE, WuY, LarsonEB (2009) Association between late-life body mass index and dementia: The Kame Project. Neurology72, 1741–1746.
6.
KuoHK, JonesRN, MilbergWP, TennstedtS, TalbotL, MorrisJN, LipsitzLA (2006) Cognitive function in normal-weight, overweight, and obese older adults: An analysis of the Advanced Cognitive Training for Independent and Vital Elderly cohort. J Am Geriatr Soc54, 97–103.
7.
BesserLM, GillDP, MonsellSE, BrenowitzW, MeranusDH, KukullW, GustafsonDR (2014) Body mass index, weight change, and clinical progression in mild cognitive impairment and Alzheimer disease. Alzheimer Dis Assoc Disord28, 36–43.
8.
LuchsingerJA, PatelB, TangMX, SchupfN, MayeuxR (2008) Body mass index, dementia, and mortality in the elderly. J Nutr Health Aging12, 127–131.
9.
BuchmanAS, WilsonRS, BieniasJL, ShahRC, EvansDA, BennettDA (2005) Change in body mass index and risk of incident Alzheimer disease. Neurology65, 892–897.
10.
JohnsonDK, WilkinsCH, MorrisJC (2006) Accelerated weight loss may precede diagnosis in Alzheimer disease. Arch Neurol63, 1312–1317.
11.
KnopmanDS, EdlandSD, ChaRH, PetersenRC, RoccaWA (2007) Incident dementia in women is preceded by weight loss by at least a decade. Neurology69, 739–746.
12.
StewartR, MasakiK, XueQL, PeilaR, PetrovitchH, WhiteLR, LaunerLJ (2005) A 32-year prospective study of change in body weight and incident dementia: The Honolulu-Asia Aging Study. Arch Neurol62, 55–60.
13.
WhiteH, PieperC, SchmaderK (1998) The association of weight change in Alzheimer’s disease with severity of disease and mortality: A longitudinal analysis. J Am Geriatr Soc46, 1223–1227.
14.
BuchmanAS, SchneiderJA, WilsonRS, BieniasJL, BennettDA (2006) Body mass index in older persons is associated with Alzheimer disease pathology. Neurology67, 1949–1954.
15.
GrundmanM, Corey-BloomJ, JerniganT, ArchibaldS, ThalLJ (1996) Low body weight in Alzheimer’s disease is associated with mesial temporal cortex atrophy. Neurology46, 1585–1591.
16.
EwersM, SchmitzS, HanssonO, WalshC, FitzpatrickA, BennettD, MinthonL, TrojanowskiJQ, ShawLM, FaluyiYO, VellasB, DuboisB, BlennowK, BuergerK, TeipelSJ, WeinerM, HampelH, Alzheimer’s Disease Neuroimaging Initiative (2012) Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer’s disease. Neurobiol Aging33, 1599–1608.
VidoniED, TownleyRA, HoneaRA, BurnsJM, Alzheimer’s Disease Neuroimaging Initiative
(2011) Alzheimer disease biomarkers are associated with body mass index. Neurology77, 1913–1920.
19.
RajanKB, SkarupskiKA, RasmussenHE, EvansDA (2014) Gene-environment interaction of body mass index and apolipoprotein E epsilon4 allele on cognitive decline. Alzheimer Dis Assoc Disord28, 134–140.
20.
VanhanenM, KivipeltoM, KoivistoK, KuusistoJ, MykkanenL, HelkalaEL, HanninenT, KervinenK, KesaniemiYA, LaaksoMP, SoininenH, LaaksoM (2001) APOE-epsilon4 is associated with weight loss in women with AD: A population-based study. Neurology56, 655–659.
21.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCRJr, KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
22.
MorminoE, BetenskyR, HeddenT, SchultzA, WardA, HujibersW, RentzD, JohnsonK, SperlingR (2014) Amyloid and APOE ɛ4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology82, 1760–1767.
23.
MorminoEC, BetenskyRA, HeddenT, SchultzAP, AmariglioRE, RentzDM, JohnsonKA, SperlingRA (2014) Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol71, 1379–1385.
24.
VosSJ, XiongC, VisserPJ, JasielecMS, HassenstabJ, GrantEA, CairnsNJ, MorrisJC, HoltzmanDM, FaganAM (2013) Preclinical Alzheimer’s disease and its outcome: A longitudinal cohort study. Lancet Neurol12, 957–965.
25.
PetersenRC, WisteHJ, WeigandSD, RoccaWA, RobertsRO, MielkeMM, LoweVJ, KnopmanDS, PankratzVS, MachuldaMM, GedaYE, JackCRJr (2016) Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol73, 85–92.
26.
MorrisJC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules.[see comment]. Neurology43, 2412–2414.
27.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
JensenMD, RyanDH, ApovianCM, ArdJD, ComuzzieAG, DonatoKA, HuFB, HubbardVS, JakicicJM, KushnerRF, LoriaCM, MillenBE, NonasCA, Pi-SunyerFX, StevensJ, StevensVJ, WaddenTA, WolfeBM, YanovskiSZ, JordanHS, KendallKA, LuxLJ, Mentor-MarcelR, MorganLC, TrisoliniMG, WnekJ, AndersonJL, HalperinJL, AlbertNM, BozkurtB, BrindisRG, CurtisLH, DeMetsD, HochmanJS, KovacsRJ, OhmanEM, PresslerSJ, SellkeFW, ShenWK, SmithSCJr, TomaselliGF, American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society (2014) 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation129(Suppl 2), S102–138.
30.
BeckerJA, HeddenT, CarmasinJ, MayeJ, RentzDM, PutchaD, FischlB, GreveDN, MarshallGA, SallowayS, MarksD, BucknerRL, SperlingRA, JohnsonKA (2011) Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol69, 1032–1042.
31.
HeddenT, MorminoEC, AmariglioRE, YoungerAP, SchultzAP, BeckerJA, BucknerRL, JohnsonKA, SperlingRA, RentzDM (2012) Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J Neurosci32, 16233–16242.
32.
JohnsonKA, GregasM, BeckerJA, KinnecomC, SalatDH, MoranEK, SmithEE, RosandJ, RentzDM, KlunkWE, MathisCA, PriceJC, DekoskyST, FischmanAJ, GreenbergSM (2007) Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol62, 229–234.
AlbersMW, TabertMH, DevanandDP (2006) Olfactory dysfunction as a predictor of neurodegenerative disease. Curr Neurol Neurosci Rep6, 379–386.
35.
GrowdonME, SchultzAP, DagleyAS, AmariglioRE, HeddenT, RentzDM, JohnsonKA, SperlingRA, AlbersMW, MarshallGA (2015) Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology84, 2153–2160.
36.
BuchmanAS, SchneiderJA, LeurgansS, BennettDA (2008) Physical frailty in older persons is associated with Alzheimer disease pathology. Neurology71, 499–504.
37.
BuchmanAS, YuL, WilsonRS, SchneiderJA, BennettDA (2013) Association of brain pathology with the progression of frailty in older adults. Neurology80, 2055–2061.
38.
KelaiditiE, CesariM, CanevelliM, van KanGA, OussetPJ, Gillette-GuyonnetS, RitzP, DuveauF, SotoME, ProvencherV, NourhashemiF, SalvaA, RobertP, AndrieuS, RollandY, TouchonJ, FittenJL, VellasB, IANA/IAGG (2013) Cognitive frailty: Rational and definition from an (I.A.N.A./I.A.G.G.) international consensus group. J Nutr Health Aging17, 726–734.
39.
BergerAK, FratiglioniL, ForsellY, WinbladB, BackmanL (1999) The occurrence of depressive symptoms in the preclinical phase of AD: A population-based study. Neurology53, 1998–2002.
40.
KimNH, KimHS, EunCR, SeoJA, ChoHJ, KimSG, ChoiKM, BaikSH, ChoiDS, ParkMH, HanC, KimNH (2011) Depression is associated with sarcopenia, not central obesity, in elderly Korean men. J Am Geriatr Soc59, 2062–2068.
41.
MorminoEC (2014) The relevance of beta-amyloid on markers of Alzheimer’s disease in clinically normal individuals and factors that influence these associations. Neuropsychol Rev24, 300–312.
42.
BurnsJM, JohnsonDK, WattsA, SwerdlowRH, BrooksWM (2010) Reduced lean mass in early Alzheimer disease and its association with brain atrophy. Arch Neurol67, 428–433.
43.
GustafsonD (2006) Adiposity indices and dementia. Lancet Neurol5, 713–720.
44.
KerwinDR, GaussoinSA, ChlebowskiRT, KullerLH, VitolinsM, CokerLH, KotchenJM, NicklasBJ, Wassertheil-SmollerS, HoffmannRG, EspelandMA, Women’s Health Initiative Memory Study
(2011) Interaction between body mass index and central adiposity and risk of incident cognitive impairment and dementia: Results from the Women’s Health Initiative Memory Study. J Am Geriatr Soc59, 107–112.
